A technology developed at Vanderbilt University Medical Center has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.
The technology, called LIBRA-seq, has helped speed up the discovery of antibodies that can neutralize SARS-CoV-2. It also enables researchers to screen antibodies against other viruses that have not yet caused human disease but which have a high potential of doing so.
“This is one way to proactively build a repertoire of potential therapeutics” against future outbreaks, said Ivelin Georgiev, Ph.D., director of the Vanderbilt Program in Computational Microbiology and Immunology and associate director of the Vanderbilt Institute for Infection, Immunology and Inflammation.
“The pathogens keep evolving, and we’re basically playing catch-up,” said Georgiev, associate professor of Pathology, Microbiology & Immunology and a member of the Vanderbilt Vaccine Center.
A more proactive approach that anticipates future outbreaks before they occur is needed to prevent a repeat of COVID-19, “or something worse happening in the future,” he said.
In their report, Georgiev and his colleagues describe the isolation of a monoclonal antibody from a patient who had recovered from COVID-19 that “shows potent neutralization” against SARS-CoV-2. It also is effective against variants of the virus that are slowing efforts to control the pandemic.
The antibody has uncommon genetic and structural characteristics that distinguish it from other monoclonal antibodies commonly used to treat COVID-19. The thought is that SARS-CoV-2 will be less likely to mutate to escape an antibody it hasn’t “seen” before.
LIBRA-seq stands for Linking B-cell Receptor to Antigen Specificity through sequencing. It was developed in 2019 by Ian Setliff, Ph.D., a former graduate student in Georgiev’s lab who now works in the biotechnology industry, and by Andrea Shiakolas, a current Vanderbilt graduate student.
Setliff wondered if he could map the genetic sequences of antibodies and the identities of specific viral antigens, the proteins markers that antibodies recognize and attack, simultaneously and in a high-throughput way. The goal was to find a faster way of identifying antibodies that will hone in on a specific viral antigen.
With the help of VUMC’s core genomics laboratory, Vanderbilt Technologies for Advanced Genomics (VANTAGE), the Vanderbilt Flow Cytometry Shared Resource, and Vanderbilt University’s Advanced Computing Center for Research and Education (ACCRE), Georgiev put Setliff’s idea to the test. It worked.
The efforts led by Setliff and Shiakolas culminated in a manuscript describing proof-of-concept development of the LIBRA-seq technology that was published in the journal Cell in 2019.
“It would have been impossible three or four years ago to move at the speed that we are right now,” Georgiev said. “A lot has changed in a very short period of time when it comes to monoclonal antibody discovery as well as vaccine development.”
When liquid meets gas, a unique zone forms. Variable by nature, molecules can cross from one state to another, combining in unique ways to either desirable or unwanted ends. From heat escaping a mug [...]
A newly detected coronavirus variant is on the rise in England, with the virus believed to be an offshoot of Delta. According to a briefing from the UK Health Security Agency, released on Friday, [...]
A team of researchers has developed a new nanomechanical technique for fast, one-step, immune-affinity tests, which can quantify the immune response induced by different COVID-19 variants in serum. Their technique provides a new tool [...]
Lawrence Livermore National Laboratory (LLNL) scientists have developed a new method for 3D printing living microbes in controlled patterns, expanding the potential for using engineered bacteria to recover rare-earth metals, clean wastewater, detect uranium, [...]
Nanomedicines may offer clinicians a way to deliver precise, targeted therapy directly to tumors without damaging surrounding tissue. Yet, progress in the development of new drugs that treat cancer at the nanoparticle level has [...]
Cambridge researchers have discovered how T cells—an important component of our immune system—are able keep on killing as they hunt down and kill cancer cells, repeatedly reloading their toxic weapons. Cytotoxic T [...]
Sunday, October 3, set records for the most COVID-19 deaths in Russia on a single day. Only 29% of people in Russia are vaccinated, despite the country being the first to approve a vaccine. [...]
New research from the University of Technology Sydney (UTS) has found that pathogens that form biofilms can evolve to survive nanosilver treatment. The study is the first to demonstrate that long-term nanosilver treatment can [...]
New variants of SARS-CoV-2 are more virulent and transmissible than the original variant of the virus. Health experts associate these variants of concern (VOCs) with increased risk of hospitalization, intensive care unit (ICU) admission, [...]
Freeze-dried genetic circuits could reveal the presence of SARS-CoV-2, Ebola, MRSA, and more. Masks and testing have been key to the COVID-19 pandemic response—and now devices that combine the two may be on the [...]
Hundreds of neuroscientists built a ‘parts list’ of the motor cortex, laying groundwork to map the whole brain and better understand brain diseases. Before you read any further, bring your hand to your forehead. [...]
An international team, led by Swinburne University of Technology and Australian National University (ANU), have made a breakthrough discovery that could potentially lead to faster, more accurate molecular or virus tests, including for COVID-19. [...]
New mutations of COVID-19, such as the Delta strain, are "getting better" at transmitting through the air, a study has found. People infected with a later variant of COVID-19 put 43 to 100 times more virus into [...]
Merck will seek U.S. approval for pill as soon as possible If approved, would be 1st oral antiviral COVID-19 drug Merck shares rally, some vaccine makers fall U.S. government to buy 1.7 mln courses [...]
An antiviral surface coating technology sprayed on face masks could provide an extra layer of protection against COVID-19 and the flu. The coating developed at The University of Queensland has already proven effective in killing [...]
Key Points Monash researchers have developed a method to prepare elongated nanocrystals to deliver therapeutic drugs Elongated nanocrystals can carry a high payload of drugs to potentially increase drug targetability and also decrease dosage [...]